Glycotherapeutics; a new class of treatment for alphavirus-induced musculoskeletal disease

糖疗法；

• 批准号: nhmrc : GNT1081954
• 负责人: Dr Lara Herrero
• 金额: $ 43.58万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/glycotherapeutics-new-class-musculoskeletal-disease/1345431
• 关键词: Glycotherapeutics; new; class; treatment; alphavirus

The hallmark of alphavirus disease is crippling pain and joint arthritis, which often has an extended duration. Currently there is no licenced specific treatment for alphavirus disease and the increasing spread of infection highlights an urgent need for therapeutic intervention strategies. This grant looks at the potential of pentosan polysulfate as a promising drug-repurposing candidate for the treatment of alphavirus-induced arthritis.

甲病毒病的标志是致残性疼痛和关节炎，通常持续时间较长。目前还没有针对甲病毒病的许可的特异性治疗方法，并且感染的日益蔓延突出了对治疗干预策略的迫切需要。这项资助着眼于戊聚糖多硫酸酯作为治疗甲病毒诱导的关节炎的有希望的药物再利用候选者的潜力。